David Shaw’s Bio-Rad Laboratories Class A BIO Stock Holding History

David Shaw’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10,000	Closed	-$4.2M	–	4449
2022 Q4	$4.2M	Sell	10,000 -500	-5%	-$202K	﹤0.01%	2255
2022 Q3	$4.38M	Buy	10,500 +10,000	+2,000%	+$4.99M	0.01%	2251
2022 Q2	$248K	Sell	500 -10,600	-95%	-$5.52M	﹤0.01%	4449
2022 Q1	$6.25M	Sell	11,100 -13,000	-54%	-$7.84M	0.01%	2066
2021 Q4	$18.2M	Buy	24,100 +1,100	+5%	+$823K	0.02%	1149
2021 Q3	$17.2M	Buy	+23,000	New	+$17.2M	0.02%	1123
2020 Q4	–	Sell	-1,500	Closed	-$773K	–	3918
2020 Q3	$773K	Hold	1,500	–	–	﹤0.01%	3011
2020 Q2	$677K	Buy	+1,500	New	+$662K	﹤0.01%	3162
2019 Q3	–	Sell	-7,600	Closed	-$2.38M	–	3810
2019 Q2	$2.38M	Hold	7,600	–	–	﹤0.01%	2127
2019 Q1	$2.32M	Buy	+7,600	New	+$2.05M	﹤0.01%	2051

Other funds holding BIO

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

David Shaw's BIO Position: Q2 2026 in Review

David Shaw increased its Bio-Rad Laboratories Class A (BIO) stake by 136% in Q2 2026, buying an estimated $3.15M and bringing the position to 19,256 shares worth $5.65M. The position accounts for ﹤0.01% of the portfolio, ranked #2296.

David Shaw first reported a position in BIO in Q2 2013 and has held it in 53 quarters since. The position peaked at $59.6M in Q3 2018. 397 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

David Shaw held 19,256 shares of Bio-Rad Laboratories Class A worth $5.65M as of Q2 2026.
David Shaw bought 11,111 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $3.15M.
Bio-Rad Laboratories Class A made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2296 holding.
David Shaw first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and has held it in 53 quarters since.
David Shaw's Bio-Rad Laboratories Class A position peaked at $59.6M in Q3 2018.
397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.